Can a One-Time gene therapy tame wet AMD for years?

NCT ID NCT05210803

ENROLLING_BY_INVITATION Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This study follows people who previously received an experimental gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see how safe and effective the treatment remains over up to five years after the injection. Participants are monitored for eye and overall health issues, as well as changes in vision. The findings could help determine if RGX-314 offers a durable, long-term option for managing this chronic eye disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RGX-314, an experimental gene therapy delivered via suprachoroidal injection
What this could lead to: If successful, this could support RGX-314 as a long-lasting treatment for wet AMD, potentially reducing the need for frequent eye injections.
What could go wrong: This is a follow-up study, not a new treatment test, and long-term safety and efficacy are still unproven. Possible risks include eye inflammation or other adverse events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)

Contacts and locations

Locations

California Retina Consultants

Bakersfield, California, 93309, United States
California Retina Consultants

Santa Barbara, California, 93103, United States
Charles Retina Institute, P.C

Germantown, Tennessee, 38138, United States
Johns Hopkins University

Baltimore, Maryland, 21205, United States
Northern California Retina Vitreous Associates Medical Group Inc

Mountain View, California, 94040, United States
Ophthalmic Consultants of Boston

Boston, Massachusetts, 02114, United States
Retina Consultants San Diego

Poway, California, 92064, United States
Retina Consultants of Texas

The Woodlands, Texas, 77384, United States
Retina-Vitreous Associates Medical Group

Beverly Hills, California, 90211, United States
Retinal Research Institute, LLC

Phoenix, Arizona, 85014, United States
Retinovitreous Associates, LTD

Philadelphia, Pennsylvania, 19107, United States
Sierra eye Associates

Reno, Nevada, 89502, United States
Southeast Retina Center PC

Augusta, Georgia, 30909, United States
Tennessee Retina, PC

Nashville, Tennessee, 37203, United States
Vision Research Center Eye Associates of New Mexico

Albuquerque, New Mexico, 87109, United States
Vitreoretinal Surgery PLLC

Edina, Minnesota, 55435, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.